OVARIAN CANCER

The United States - a study found, abdominal pain and distension, and ovarian cancer-related symptoms, usually in the months before diagnosis will appear. This shows that the use of appropriate methods of early diagnosis of ovarian cancer, timely treatment to reduce deaths.
According to a Reuters report, the University of California research study found that patients with breast cancer and non-cancer than women with ovarian cancer are more vulnerable to representation symptoms, the most notable of these patients are diagnosed in the first half of the abdominal pain and distension. Researchers in the October edition of the American "cancer" on the magazine report said that the current practice is to use general diagnostic imaging abdominal and pelvic imaging and CA125 to confirm the diagnosis of ovarian cancer. The researchers suggested that doctors should consider allowing representation of the above symptoms of ovarian cancer early women do pelvic imaging and CA125 to early treatment.

Disease Overview

Patients with malignant ovarian tumor when treatment is late (> Phase II), ovarian cancer is the surgical treatment called tumor or cytoreductive surgery or large resection.
Surgery is to do everything possible to the original tumor resection and can see the pots, peritoneal metastasis, so that each region of residual lesion diameter of less than 2.0 cm to 1.5 cm. Intraoperative from ascites fluid or cells for blood screening. Because ovarian and uterine cancer often, the annex or visco-invasion, peritoneal and keep pots, it is more of "carpet-volume" or "dumplings", from extraperitoneal space elements from the peritoneal wall, bladder and pelvic floor serous peritoneal, along with the uterus and pelvic peritoneum block tumor resection. The pots have peritoneal metastasis tissues or organs should be possible to complete resection or partial resection, resection of the omentum, some intestinal resection, resection of the bladder or ureter shifting values. The removal of the tumor as possible aim is to enhance postoperative radiotherapy and chemotherapy effect. The merger of ovarian cancer ascites, regardless of whether all resection are advised to intraperitoneal indwelling catheter for intraperitoneal injection of anti-cancer drugs. Anti-cancer drugs or radioisotopes for preparation also can be injected directly unresectable tumors.
Surgery can not decide in its benign and malignant ovarian tumor resection specimens should be admitted or contralateral ovarian tissue frozen tablets sent for histopathologic examination. There is no such conditions, generally after the contralateral normal ovarian As can be temporarily retained, pathological specimens were sent checks to clear in nature, and close observation. The previous suspected metastatic ovarian tumor and failed to find its source, should be in operation in detail in the original exploration of abdominal lesions, after further treatment for reference.

Diagnosis
Not obvious early symptoms of ovarian cancer, so early diagnosis depends on the regular census.

1. Past history should be asked whether particular pelvic mass or the recent history of tumor growth. Women over 40 years of age and unexplained gastrointestinal symptoms, and should be gynecological examinations.
2. Body check, can be found abdominal mass, ascites positive sign.
3. Gynecological examinations beside mass, although it is solid or cystic, irregular activities of the poor, and often bilateral. Triple consultation found dome nodule or mass.
4. Auxiliary

Ovarian cancer, particularly early ovarian cancer often complained that no symptoms, but the New York researchers report that some diseases may actually cause the symptoms can be identified, even early can.

Shilongkaite Haven of Hope Cancer Center (Memorial Sloan-Kettering Cancer Center) Shalaaoersen (Sara H. Olson) doctors said, of ovarian cancer are often considered "unclear and non-specific", but she and colleagues conducted a study indicated that, although patients with ovarian cancer the symptoms in healthy women is very unusual, but in essence, patients with more common, slightly different.

When ovarian cancer is often diagnosed late has come. As of early ovarian cancer five-year survival rate was 70% to 90%, while the terminally ill 5-year survival rate is only 20% to 30%, therefore early diagnosis is of great significance.

American researchers recently found that some symptoms can help people detect early ovarian cancer. Research on 128 patients with pelvic cancer patients and 1,709 women were studied retrospectively. Results showed that patients with malignant monthly developed symptoms 20 to 30, while patients with benign or control group of women developed symptoms two per month to three times, usually occurs in Wai menstrual cycle. More serious symptoms of patients with malignant tumors, but often in the early pathogenesis. In addition, the combination of symptoms is very important, 43% of the cancer patients while bloating, abdominal circumference and increased urinary symptoms, and the control group while the combination of these symptoms only 8%.

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.